Elite Pharmaceuticals, Inc. ( OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal ...
NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and ...
Q3 2025 Earnings Call November 17, 2025 8:30 AM ESTCompany ParticipantsMatthew Duffy - Chief Business Officer & ...
There are now over 200 carriers offering cyber insurance products in the US alone. That heightened competition has accelerated innovation and helped bring more client-centric solutions to market—but ...
Cannabis retailers and product manufacturers are moving away from potency and embracing products that offer "functional THC." ...
In a statement to Xbox Era, Activision said, “Like so many around the world, we use a variety of digital tools, including AI tools, to empower and support our teams to create the best gaming ...
Jack Kelliher of Racing and Sports explains just how to maximise a horse racing product, and why punters will keep coming ...
In the past, biosimilar makers have been able to invalidate some of those patents through a sped-up process called “inter ...
Propellants in asthma inhalers produce greenhouse gas emissions equivalent to driving 200 miles, yet most healthcare systems ...
The rise and fall of shanzhai phones were swift; they not only created stories of dozens of billionaires emerging from mere "one-meter counters" in Huaqiangbei but also witnessed tragedies like that ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback